Sign in to view content

Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy

Glenn J. Jaffe, MD

Video
Published 2022

Related

Episode 12: RPE Stem Cells for Dry AMD with Dr. Mark Humayun
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Early Progression of Atrophy in AMD: Post Hoc Analysis From the GATHER1 Study
David R Lally, MD
Annual Meeting Talks
2022
Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021

Category: AMD-Non-Neovascular

See more